Brexafemme® (ibrexafungerp) – New indication
December 1, 2022 - Scynexis announced the FDA approval of Brexafemme (ibrexafungerp), in adult and post-menarchal pediatric females, for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).
Download PDF
